RxDoctor Payments Data

Veluvolu Rao, MD

Internal Medicine · Milwaukee, WINPI 1437148855

Payments from drug & device makers

$2,092in general payments, 2019–2025

Across 66 payments — averaging $31.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$418
  • Boehringer Ingelheim$322
  • AstraZeneca$291
  • Novartis$246
  • AbbVie$183
  • Johnson & Johnson$160
  • plus $473 from 12 others

What the payments were for

  • Food & beverage$1,98595%
  • Education$1075%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,092 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$57,773
Medicare patients
133
Services billed
504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide31$48,313
JardianceEmpagliflozin39$40,767
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,824
JanuviaSitagliptin Phosphate18$21,947
EliquisApixaban13$10,089
Breo ElliptaFluticasone/Vilanterol16$8,527
SymbicortBudesonide/Formoterol Fumarate23$7,324
JanumetSitagliptin Phos/Metformin Hcl13$7,008
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,414
Atorvastatin Calcium530$4,209
Febuxostat21$3,986
Potassium Chloride130$3,322
Albuterol Sulfate HfaAlbuterol Sulfate132$3,264
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,152
Lidocaine21$2,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Olanzapine$22$49,38347 claims
Boehringer IngelheimJardiance$322$40,76739 claims
MerckJanuvia, Janumet$23$28,95631 claims
PfizerEliquis$418$10,08913 claims
AstraZenecaSymbicort$291$7,32423 claims
AbbVieSynthroid$183$1,68721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →